Nasus Pharma Ltd
NS002
anaphylaxis
Countdown
116days
Phase 3 readout · ~ Oct 31, 2026 estimated
What's at stake
Phase 3 trial results for NS002 in anaphylaxis are due ~ Oct 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“pivotal clinical study expected to initiate in the fourth quarter of 2026 and a planned readout in the first quarter of 2027, subject to regulatory alignment.”